Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Active, not recruiting · NCT06011109 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06011109 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aveta Biomics, Inc. | 4 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic | Rochester | United States | 664 |
| University of Nebraska Medical Center | Omaha | United States | 397 |